Related Experiment Video
Updated: Feb 16, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
Natural History of Moderate Coronary Artery Stenosis After Surgical Revascularization
Sajjad Raza1, Eugene H Blackstone2, Penny L Houghtaling3
1Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
Insights
Grafting moderately stenosed coronary arteries (MSCAs) accelerates disease progression, particularly with saphenous vein grafts. However, internal thoracic artery grafts offer excellent long-term protection against myocardial ischemia, making them a viable option for MSCA treatment.
Area of Science:
- Cardiovascular Surgery
- Interventional Cardiology
- Vascular Biology
Background:
- Controversy exists regarding the impact of grafting moderately stenosed coronary arteries (MSCAs) on native vessel disease progression.
- The protective effect of grafting against late myocardial ischemia is also debated.
Purpose of the Study:
- To investigate the influence of coronary artery bypass grafting (CABG) on the progression of disease in native moderately stenosed coronary arteries (MSCAs).
- To evaluate the protective effect of CABG against late myocardial ischemia in patients with MSCAs.
Main Methods:
- Analysis of 55,567 patients undergoing primary isolated CABG from 1972 to 2011.
- Focus on 1,902 patients with a single MSCA and postoperative angiograms.
- Comparison of disease progression in grafted (internal thoracic artery [ITA] and saphenous vein [SV]) versus nongrafted MSCAs.
Main Results:
- Native-vessel disease progressed faster in grafted MSCAs compared to nongrafted ones (3.6x faster with ITA, 10x faster with SV).
- Internal thoracic artery (ITA) grafts demonstrated excellent long-term patency rates.
- ITA grafts provided significant protection against myocardial ischemia over time.
Conclusions:
- While grafting accelerates MSCA disease progression, ITA grafts offer superior long-term patency and protection from myocardial ischemia.
- Internal thoracic artery grafting of moderately stenosed coronary arteries should be considered for improved patient outcomes.
Background:
It remains controversial whether grafting moderately stenosed coronary arteries (MSCAs) influences native-vessel disease progression and whether grafting may protect against late myocardial ischemia.
Methods:
From 1972 to 2011, 55,567 patients underwent primary isolated coronary artery bypass grafting (CABG); 1,902 had a single coronary artery with angiographically moderate (50% to 69%) stenosis and ≥1 postoperative angiogram. Disease progression was studied in 489 nongrafted, 371 internal thoracic artery (ITA)-grafted, and 957 saphenous vein (SV)-grafted MSCAs, as well as patency of 376 ITA and 1,016 SV grafts to these MSCAs.
Results:
At 1, 5, 10, and 15 years, native-vessel disease progressed from moderate to severe stenosis/occlusion in 32%, 52%, 66%, and 72% of nongrafted MSCAs; 55%, 73%, 84%, and 87% of ITA-grafted MSCAs; and 67%, 82%, 90%, and 92% of SV-grafted MSCAs. After adjusting for patient characteristics, MSCA disease progressed 3.6 times faster with ITA and 10 times faster with SV grafting compared with nongrafting. At these same time points, occlusion of ITA grafts to MSCAs was 8%, 9%, 11%, and 15% and for SV grafts, 13%, 32%, 46%, and 56%; protection from myocardial ischemia by ITA-grafted versus nongrafted MSCAs was 29%, 47%, 59%, and 61%.
Conclusions:
Most MSCAs progress to severe stenosis or occlusion in the long term. Progression is faster in grafted than nongrafted MSCAs, more so with SV than ITA grafts. However, ITA grafts to such arteries have excellent patency, providing long-term protection from myocardial ischemia. Therefore, ITA grafting of MSCAs should be considered.
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
What is Evolutionary History?
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease IV: Preventive Measures

